News >

PFS Improved With Maintenance Rucaparib in Recurrent Ovarian Cancer Irrespective of Prior Chemo

Wayne Kuznar
Published: Wednesday, Nov 07, 2018

Domenica Lorusso, MD

Domenica Lorusso, MD

In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor rucaparib (Rubraca) as maintenance treatment improved progression-free survival (PFS) versus placebo, despite the number of chemotherapy regimens. These data were part of a subgroup analysis of the phase III ARIEL3 study, which were presented at the 2018 ESMO Congress.1

Results showed that patients in ARIEL3 who received either 2 or ≥3 prior lines of chemotherapy had an improvement in PFS. This finding was consistent across the intent-to-treat (ITT) population, those with BRCA-mutant tumors, and the “BRCA-like” population, which consists of BRCA wild-type/high loss of heterozygosity (LOH), reported Domenica Lorusso, MD, of the Fondazione IRCCS Instituto Nazionale de Tumori and MITO, Milan, Italy, during the meeting.

The double-blind, placebo-controlled, ARIEL3 trial enrolled 564 patients across 11 countries with platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma who had received at least 2 previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a performance status of 0 or 1, and had adequate organ function.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Community Practice Connections™: Evolutions in the Treatment and Management of Advanced Cervical Cancer: Leveraging the Immunosuppressive Microenvironment, Addressing Ongoing Clinical NeedsJun 30, 20201.5
Publication Bottom Border
Border Publication